Swiss drugmaker Roche's logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann
Jan 20 (Reuters) - Roche's Genentech said on Tuesday it will more than double its initial investment in a biomanufacturing facility in North Carolina to about $2 billion, as the companies look to further boost their $50 billion investment in the U.S.
The facility, based in Holly Springs, North Carolina is set to be operational by 2029 and will produce next-generation treatments for metabolic conditions, such as obesity.
